Overview

* Vertex Q3 2025 revenue grows 11% yr/yr, beating analyst expectations

* Adjusted EPS for Q3 2025 beats consensus, reflecting strong operational performance

* Adjusted net income for Q3 2025 missed analyst estimates

Outlook

* Vertex expects full-year 2025 revenue of $11.9 to $12.0 bln

* Company revises 2025 non-GAAP tax rate guidance to 17% to 18%

* Vertex anticipates continued growth in CF therapies and launches

Result Drivers

* CF THERAPIES - Strong demand for cystic fibrosis therapies, including ALYFTREK, drove revenue growth

* NEW LAUNCHES - Contributions from CASGEVY and JOURNAVX supported revenue growth

* R&D INVESTMENT - Increased R&D spending to support clinical development programs and new launches

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $3.08 $3.05

REVENUE bln bln (27

Analysts

)

Q3 Beat $4.80 $4.56

ADJUSTED (23

EPS Analysts

)

Q3 EPS $4.20

Q3 Miss $1.08 $1.19

Adjusted bln bln (19

Net Analysts

Income )

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 12 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Vertex Pharmaceuticals Inc ( VRTX ) is $481.50, about 11.6% above its October 31 closing price of $425.57

* The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 23 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)